Description

Overview

LL-37 5mg is a synthetic research peptide referenced in scientific and preclinical literature for the study of antimicrobial peptides, innate immune signaling, and cellular defense mechanisms within controlled laboratory environments. Supplied exclusively for research use, this compound supports structured investigations focused on peptide characterization, assay development, and reproducible experimental workflows. Current research involving LL-37 (a human cathelicidin peptide) is conducted in non-clinical settings, where investigators examine its interaction with microbial membranes, immune signaling pathways, and cytokine activity. Experimental models commonly explore LL-37’s role in host defense responses, peptide–membrane interactions, and its influence on cellular behavior under controlled experimental conditions. In in vitro systems, researchers may assess peptide stability, binding properties, and response variability across different laboratory models. All available data on this compound is strictly limited to laboratory-based research. No claims are made regarding therapeutic applications, clinical efficacy, physiological outcomes, or suitability for human or veterinary use.

Biochemical Characteristics

LL-37 5mg is a synthetic research peptide referenced in scientific literature for its relevance to antimicrobial activity, membrane interaction, and innate immune signaling pathways. All characterization of this compound is conducted strictly through physicochemical evaluation and controlled laboratory research protocols. Biochemical assessment of LL-37 typically includes confirmation of peptide identity, purity profiling using advanced chromatographic techniques, molecular weight verification, and stability analysis under regulated laboratory conditions. In preclinical research environments, experimental models may investigate its interaction with lipid membranes, microbial structures, and immune-related signaling pathways. Studies may also evaluate peptide stability following reconstitution and its behavior across controlled in vitro systems designed for reproducible scientific analysis. All documentation and evaluation of this compound remain limited to investigational, non-clinical laboratory settings. No claims are made regarding therapeutic use, clinical application, physiological effects, or suitability for human or veterinary use.

Molecular Class: Synthetic antimicrobial peptide (cathelicidin analog)

Peptide Composition: LL-37 (37-amino-acid human cathelicidin peptide)

Purity: Research-grade, high-purity peptide material

Material State: Lyophilized peptide powder

Quantity: 5mg per vial

Intended Use: Laboratory research only

Research Applications

Within scientific and preclinical literature, LL-37 5mg is referenced as a synthetic research peptide evaluated exclusively in controlled, non-clinical laboratory environments. Its use is limited to analytical investigation, peptide–membrane interaction studies, and innate immune pathway modeling conducted under structured experimental protocols.

Documented laboratory research contexts may include:

• Molecular signaling studies examining peptide involvement in innate immune pathways, cellular defense mechanisms, and regulatory signaling processes within controlled biochemical systems
• Peptide interaction analysis focused on membrane binding behavior, antimicrobial activity modeling, and interaction with lipid bilayers in regulated laboratory settings
• Cellular response evaluation within experimental models designed to assess immune-related signaling, cytokine activity, and cellular behavior under induced conditions
• Peptide stability and structural integrity testing following reconstitution, as well as under controlled storage and handling conditions
• Comparative peptide research exploring structural and functional relationships between antimicrobial peptides and related compounds within broader immunological research frameworks
• Analytical benchmarking procedures utilizing validated reference standards, chromatographic verification, and laboratory quality control assessments

All referenced applications remain strictly confined to laboratory-based investigation and non-clinical experimental use. No statements are made regarding biological outcomes, therapeutic use, clinical relevance, or applicability beyond structured research settings.

Pathway / Mechanistic Context

In experimental and preclinical research literature, LL-37 5mg is referenced in relation to antimicrobial peptide activity, membrane interaction dynamics, and innate immune signaling pathways examined at the molecular and biochemical interaction level. These investigations are conducted strictly within controlled laboratory environments to support structured analysis of peptide-driven interactions, signaling activity, and downstream pathway modulation under defined experimental conditions. Scientific discussion surrounding LL-37 (a human cathelicidin peptide) commonly highlights its relevance within models of host defense mechanisms and immune-related signaling activity. Within laboratory research systems, mechanistic evaluation may include observation of peptide–membrane interactions, modulation of cytokine-associated signaling pathways, assessment of intracellular responses, and mapping of regulatory signaling interactions under controlled in vitro conditions. Experimental models may also explore LL-37 behavior in relation to microbial membrane disruption, cellular signaling balance, and stress-response pathways within defined biochemical environments. All mechanistic interpretations remain observational and exploratory in nature and are confined exclusively to non-clinical research settings. No representations extend beyond controlled experimental frameworks, and no claims are made regarding biological outcomes, clinical relevance, or applicability outside structured investigational use.

Preclinical Research Summary

Preclinical research literature references observational findings related to LL-37 5mg derived from controlled experimental systems designed to evaluate antimicrobial peptide activity, membrane interaction behavior, and innate immune signaling dynamics within non-clinical research frameworks. These investigations focus on laboratory-based analysis of peptide identity confirmation, interaction with microbial and cellular membranes, molecular stability profiling, and pathway activity under defined analytical conditions. Exploratory research discussions frequently involve evaluation within cellular and biochemical models associated with host defense mechanisms and immune-related signaling systems examined in structured laboratory environments. Additional analyses may include assessment of peptide stability under varied storage conditions, structural integrity following reconstitution, mapping of interaction patterns within membrane-associated and cytokine-related signaling pathways, and observation of downstream intracellular responses within regulated in vitro and preclinical experimental systems. All documented observations remain confined to investigational, analytical, and preclinical laboratory contexts and are presented solely for exploratory scientific research purposes. No findings imply clinical relevance, therapeutic application, physiological effects, or suitability for human or veterinary use. All references are limited exclusively to controlled laboratory research environments.

Form & Analytical Testing

LL-37 5mg is supplied as a research-grade synthetic peptide manufactured under controlled production standards to ensure batch consistency, identity verification, and high-purity specifications suitable for laboratory analysis. The compound is provided in lyophilized peptide powder form, supporting stable storage conditions and standardized preparation procedures within structured analytical and experimental research workflows. Material verification focuses on physicochemical characterization and quality parameters relevant to peptide integrity, structural stability, and interaction studies. Analytical evaluation typically includes peptide identity confirmation, purity assessment using validated chromatographic techniques such as high-performance liquid chromatography (HPLC), and batch consistency verification. Additional methods may involve molecular mass determination via mass spectrometry and stability testing under defined laboratory storage and handling conditions. All testing, validation, and quality control procedures are conducted exclusively to support material characterization within controlled, non-clinical laboratory research environments.

Referenced Citations

Dürr, U. H. N., et al. (2006). LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochimica et Biophysica Acta (BBA) – Biomembranes. Hancock, R. E. W., & Sahl, H.-G. (2006). Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nature Biotechnology. Nijnik, A., & Hancock, R. E. W. (2009). Host defence peptides: antimicrobial and immunomodulatory activity and potential applications for tackling antibiotic-resistant infections. Emerging Health Threats Journal. Mookherjee, N., et al. (2006). Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. Journal of Immunology. Scott, M. G., et al. (2002). An anti-infective peptide that selectively modulates the innate immune response. Nature Biotechnology. Wang, G. (2014). Human antimicrobial peptides and proteins. Pharmaceuticals. Bals, R., & Wilson, J. M. (2003). Cathelicidins—a family of multifunctional antimicrobial peptides. Cellular and Molecular Life Sciences. Turner, J., et al. (1998). Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrobial Agents and Chemotherapy.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. FOR RESEARCH USE ONLY (RUO). NOT FOR HUMAN OR VETERINARY USE.

RUO Disclaimer

All products offered on this website, including LL-37 5mg, are intended strictly for in vitro laboratory research purposes only. In vitro research refers to experimental procedures conducted outside of living organisms within controlled laboratory environments for analytical and investigative study. These materials are not classified as drugs, pharmaceuticals, dietary supplements, or medical products. They have not been reviewed, evaluated, or approved by the U.S. Food and Drug Administration (FDA) for the diagnosis, treatment, cure, or prevention of any disease or medical condition. Any use outside structured laboratory research—including administration to humans or animals—is strictly prohibited. For Laboratory Research Use Only (RUO). Not for human use, medical use, diagnostic use, or veterinary use.